Hartwig Medical Foundation welcomes new managing director

Hartwig Medical Foundation is pleased to announce that Robert Jan Lamers has joined the organization as its new managing director, effective September 1. He steps into the role after Hans van Snellenberg. Lamers’ arrival marks a new phase for Hartwig, as the organization evolves from a pioneer in DNA analysis into a leading innovator in data-driven, personalized cancer care.
At the interface of healthcare and data
Lamers has a background in biotechnology and over twenty years of experience leading innovative organizations at the crossroads of healthcare, data, and technology. He has previously headed several scale-ups and built a strong network within the (international) biotech- and healthcare sectors.
‘In Robert Jan Lamers we have found a new managing director who will build on the success of Hartwig Medical Foundation. With his leadership, we aim to accelerate progress even further and expand access for patients and physicians to precision diagnostics and personal treatments. He is a unifying leader with strategic vision who will guide Hartwig into its next phase of impact and growth.’ – Constantijn van Oranje, chair of the Supervisory Board of Hartwig Medical Foundation.

Driving greater impact
Lamers is eager to begin this new chapter with Hartwig Medical Foundation.
You read an article in the category Hartwig Medical Foundation. All news‘What appeals to me about Hartwig is the unique combination of patient focus, innovation, scientific depth, and societal impact. Together with dedicated partners and a strong team, we are committed to advancing cancer care. I look forward to meeting our partners and working together to achieve even greater impact for more patients.’ – Robert Jan Lamers
Also read
Collaboration as the foundation for faster, better, and more affordable diagnostics
For Kees van den Berg, the CEO of GenomeScan, the collaboration between his organization and the Hartwig Medical Foundation is …
Comprehensive molecular diagnostics closer for more patients thanks to price reduction
Hartwig Medical Foundation reduces the price of its OncoAct Whole Genome Sequencing (WGS) service as of January 1, 2026. This …
Screening for T cells that already fight the tumor: Hartwig’s pipeline in practice
By Laura Nederveen In the search for more effective cancer treatments, Alena Gros and her team at Vall d’Hebron Institute …
The number of WGS samples Hartwig Medical Foundation has is quite unique in the research field and is rapidly growing. It amounted to 3.500 samples when we started and it’s already over 5.000 now.